七月 2026
- Home
- RaQualia Pharma
七月 2026的RaQualia Pharma市场份额分析
raqualia pharma is engaged in the marketing and licensing of intellectual property from the research and development of pharmaceuticals and clinical development candidates. with a business model based on the concept of an open research and development collaboration network, we will strive to achieve our vision to "contribute to human hope, health, and happiness through the discovery and development of new medicines"
RaQualia Pharma(包含公司地区分支机构)
查看更多网站流量和参与度信息- raqualia.com
RaQualia Pharma收入截至 七月 2026为 15M - 25M
RaQualia Pharma主要域名产生的收入
3 年中RaQualia Pharma主要域名的收入
RaQualia Pharma主要域名的收入
七月 2026的RaQualia Pharma股票价格
RaQualia Pharma的股票交易代码为 4579。您可以在下面查看过去 12 个月的RaQualia Pharma股票表现(最多 七月 2026)
RaQualia Pharma热门域名的总访问量
了解RaQualia Pharma市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
RaQualia Pharma热门域名的平均访问时长
分析RaQualia Pharma参与度指标。
过去 3 个月的平均访问时长
子公司明细
RaQualia Pharma热门域名的平均页面浏览量
了解RaQualia Pharma如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
RaQualia Pharma 采用的主要技术
这些是排名前 RaQualia Pharma 的顶级域名所使用的网站技术(按行业分列)
准备好发现优质潜在客户了吗?
借助 Similarweb 销售情报解决方案,确定任意网站使用了哪些技术来设计完美的销售宣传,并缩短销售周期。
RaQualia Pharma 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻RaQualia Pharma Inc. is developing RQ-00000007.In addition to the acute pain indication, RaQualia is developing RQ-00000007 as a new, innovative therapy for the treatment of chronic pain, cancer, and autoimmune diseases.
八月 4, 2010阅读更多
新闻Veritas In Silico Inc. partners with RaQualia Pharma Inc..Japan-based startup Veritas In Silico has entered into a joint drug discovery research agreement with RaQualia Pharma to create innovative small molecule drugs targeting messenger RNA (mRNA) by integrating RaQualia Pharma’s small molecule drug discovery technology and Veritas In Silico’s platform technology specialised in drug discovery against mRNA targets.
十二月 31, 2022阅读更多
新闻RaQualia Pharma Inc. partnered with Eli Lilly on Aug 21st '18.RaQualia Pharma Inc. (RaQualia), headquartered in Aichi, Japan, a drug discovery and development company with innovative research capabilities, today announced that it has entered into a worldwide collaboration and licensing agreement with Eli Lilly and Company (Lilly), a global pharmaceutical company headquartered in Indianapolis, Indiana, United States.
八月 20, 2018阅读更多
查看 RaQualia Pharma 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
